What does this research mean for the field?

After anthracycline chemotherapy, myocardial glucose uptake increases and fatty acid oxidation decreases, indicating altered myocardial metabolism associated with cardiotoxicity. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate anthracycline-induced myocardial energy metabolism changes using integrated 18F-FDG PET/CT and data-independent acquisition (DIA) proteomics to discover targets for predicting cardiotoxicity.

January 10, 2026Frontiers in Cardiovascular MedicineOpen Access

Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration of 18F-FDG PET/CT and data-independent acquisition proteomics

Q: What are the key findings of this study?

After anthracycline chemotherapy, LV SUV max increased significantly to 4.82, indicating altered myocardial glucose uptake and decreased fatty acid oxidation associated with cardiotoxicity.

View Full Paper

Ask AI

Bookmark

Key result

Anthracycline chemotherapy raises LV SUVmax to ~4.8, indicating altered glucose uptake linked to cardiotoxicity.

Why the study?

To investigate anthracycline-induced cardiotoxicity myocardial metabolism changes by integrating 18F-FDG PET/CT and data-independent acquisition proteomics to provide novel prediction targets.

Does anthracycline-based chemotherapy alter myocardial energy metabolism as measured by 18F-FDG PET/CT and DIA proteomics in patients with diffuse large B-cell lymphomas?

Population

17 patients with DLBCL receiving anthracycline-based chemotherapy and 13 non-oncologic controls without organic heart disease

Comparison

Anthracycline-treated DLBCL patients (before vs after 6 cycles) vs non-oncologic controls

Design

Observational cohort study

Follow-up

6 cycles of chemotherapy

Authors

YXYining XuNanjing University of Chinese Medicine YCY J ChenNanjing University of Chinese Medicine SZShujie ZhangNanjing University of Chinese Medicine

Discussion

Member takes

Implication

May enable earlier PET/CT detection of anthracycline cardiotoxicity; hypothesis-generating for surveillance before echocardiographic changes.

Key Points

To investigate anthracycline-induced myocardial energy metabolism changes using integrated 18F-FDG PET/CT and data-independent acquisition (DIA) proteomics to discover targets for predicting cardiotoxicity.
Enrolled 30 diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy, including 17 final participants (DLBCL group), alongside 13 non-oncologic controls without organic heart disease in China (ChiCTR2400088740).
Performed 18F-FDG PET/CT imaging before and after 6 cycles of chemotherapy in the DLBCL group (and once in controls) to measure LV SUVmax and LV SUVmean.
Collected serum samples before and after chemotherapy to analyze alterations in myocardial metabolism using DIA proteomics.
Post-chemotherapy LV SUVmax increased significantly from a baseline median of 2.40 (95% CI: 2.04–2.74) to 4.82 (95% CI: 3.50–6.05; P < 0.05), and LV SUVmean increased from 1.34 (95% CI: 1.15–1.55) to 1.93 (95% CI: 1.57–2.56; P < 0.05).
Abnormal 18F-FDG myocardial uptake was significantly higher post-chemotherapy compared with baseline and controls (P < 0.001), characterized by increased diffuse and focal-on-diffuse uptake (P < 0.01).
DIA proteomics demonstrated significant post-treatment downregulation of fatty acid metabolism enzymes CPT1A, ACOX1, ECH1, and ACAT1, which correlated negatively with left ventricular SUV.

Structured PICO

Does anthracycline-based chemotherapy alter myocardial energy metabolism as measured by 18F-FDG PET/CT and DIA proteomics in patients with diffuse large B-cell lymphomas?

Population

30 adults (17 with diffuse large B-cell lymphomas and 13 non-oncologic controls without organic heart disease), mean age 63.65 in DLBCL group, 64.7% male. Key inclusion: DLBCL treated with anthracycline-based chemotherapy.

Intervention

6 cycles of anthracycline-based chemotherapy (R-CHOP regimen containing epirubicin 70 mg/m2 or liposomal doxorubicin 25 mg/m2)

Comparator

Non-oncologic participants without organic heart disease who did not receive any drug intervention

Outcome

Changes in myocardial metabolism measured by left ventricular maximum standardized uptake value (LV SUVmax) and left ventricular mean standardized uptake value (LV SUVmean) via 18F-FDG PET/CT before and after 6 cycles of chemotherapysurrogate

Anthracycline-based chemotherapy induces early myocardial metabolic remodeling characterized by decreased fatty acid oxidation and increased glucose uptake, detectable by 18F-FDG PET/CT before functional echocardiographic changes occur.

Cite This Study

Xu et al. (2026) studied this question. After anthracycline chemotherapy, LV SUV max increased significantly to 4.82, indicating altered myocardial glucose uptake and decreased fatty acid oxidation associated with cardiotoxicity.

synapsesocial.com/papers/696321db91e05aa366cb8274 https://doi.org/10.3389/fcvm.2025.1726943

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark

Implication

May enable earlier PET/CT detection of anthracycline cardiotoxicity; hypothesis-generating for surveillance before echocardiographic changes.

Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration of 18F-FDG PET/CT and data-independent acquisition proteomics

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration of 18F-FDG PET/CT and data-independent acquisition proteomics

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider